Ledger.Open graph →
SEC Form D · filed May 10, 2017

Fulcrum Therapeutics, Inc

Offering
$5.0M
Sold
$5.0M
Exemption
Rule 506(b)
Industry
Biotechnology
Location
CAMBRIDGE, MA
Type

Rule 506(b): private placement to accredited investors, no public advertising.

People & firms on this filing (14)

James Geraghty · Cambridge, MADirectorRobert Gould · Cambridge, MAExec · DirectorMark Levin · Cambridge, MADirectorAlan Ezekowitz · Cambridge, MADirectorJames Collins · Cambridge, MADirectorJennifer W. Cattier · New York, NYDirectorPatrick Whalen · Millville, DEDirectorMatthew W. Kaplan · New York, NYExec · DirectorSharon Berberich · St. Louis, MODirectorRichard R. Gilliam · Vancouver, British Columbia, CanadaDirectorPaddy Dear · Grand Cayman, Cayman IslandsExec · DirectorReade Griffith · Grand Cayman, Cayman IslandsDirectorDavid Chase · Seattle, WADirectorMelissa Taylor · Seattle, WADirector

Public SEC Form D (Reg D) filing. · View issuer on SEC EDGAR ↗